ClinicalTrials.gg
RecruitingNCT06706076SOLARAUpdated Nov 4, 2026

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

A Phase 1/2 interventional study of BH-30643 and BH-30643 combo therapy with Carboplatin/Pemetrexed in NSCLC (Advanced Non-small Cell Lung Cancer), sponsored by BlossomHill Therapeutics. Recruiting at 43 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by BlossomHill Therapeutics · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 4, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
675
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 40 under way, 12 of them phase 3. Carboplatin · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
9th of 251
675 · median 55
Started
2025
with 4 others
Phase 1/2
25 of 272
2 open now
Primary completion
2029-01
later than 32 of 39 live
Registered
261st of 272
by date

Among the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by planned enrollment of the 251 interventional ones that give a count, is one of 5 that started in 2025, is one of 25 in phase 1/2, reaches primary completion later than 32 of the 39 other live ones, and was the 261st registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 272 studies testing carboplatin in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This Phase1/2, open label, multicenter study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of BH-30643 in patients with NSCLC having EGFR and/or HER2 mutations.

Phase 1 will determine the recommended Phase 2 dose (RP2D) and, if applicable, the maximum tolerated dose (MTD) of BH-30643, both as a monotherapy and in combination with chemotherapy.

Phase 2 will further evaluate the antitumor efficacy and safety in specified cohorts determined by EGFR/HER2 mutation subtypes and/or treatment history at the RP2D, as well as the population PK.

Read the detailed description

BH-30643 is a novel, orally available, non-covalent, macrocyclic, mutant selective OMNI-EGFR inhibitor that targets a broad diversity of mutations in the EGFR kinase domain. These include EGFR classical mutations (e.g., ex19del and L858R) as well as less common (atypical) mutations (including G719X, S768I, L861Q, E709X, and beyond). BH-30643 also overcomes a variety of mutations which can cause resistance to previously approved EGFR TKIs (including both C797S and T790M). BH-30643 was designed to be selective over wildtype EGFR and HER2.

03

Conditions studied

  • NSCLC (Advanced Non-small Cell Lung Cancer)

Keywords

  • NSCLC
  • Locally Advanced NSCLC
  • Metastatic NSCLC
  • Non-small Cell Lung Cancer
  • HER2 mutation
  • EGFR mutation
  • EGFR classical mutation
  • EGFR atypical mutation
  • EGFR exon20 insertion
  • EGFR uncommon mutation
  • EGFR resistant mutation
  • BH-30643
  • Tyrosine kinase inhibitor
  • TKI
  • EGFR
  • OMNI-EGFR
  • EGFR kinase domain mutations
  • EGFR common mutation
  • EGFR activating mutation
  • Ex19del
  • EGFR del E746_A750
  • Exon 19 deletion
  • L858R
  • C797S
  • C797G
  • C797X
  • T790M
  • G719X
  • G724X
  • L718V
  • L718X
  • L861Q
  • S768I
  • S768X
  • E709X
  • L747X
  • Exon 19 insertion
  • L833X
  • L861X
  • V769X
  • V834X
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years or legal adult.
  • confirmed diagnosis of locally advanced or NSCLC with EGFR or mutations in the kinase domain of exons 18, 19, 20, or 21.
  • Has at least 1 measurable target extracranial lesion according to v1.1.
  • Performance Status ≤ 1.
  • Has a of ≥ 3 months.
  • Has adequate hematologic, hepatic, and renal function.

    • The above are a summary; other Inclusion Criteria details may apply.

Exclusion criteria

Exclusion Criteria:

  • History of any concurrent within the previous 2 years.
  • Known other oncogenic driver alterations (eg, moderate or high MET amplification) or histological transformation (eg, to small cell carcinoma, etc.).
  • Unresolved toxicities from prior therapies.
  • Any significant and uncontrolled medical condition, such as infection.
  • Active or history of interstitial lung disease from any cause
  • cardiovascular event within 6 months or significant history of major organ.

    • The above are a summary; other Exclusion Criteria details may apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
675 participants (estimated)

Study arms

  • Experimental
    Phase 1 Monotherapy Dose Escalation and Expansion

    * BH-30643 monotherapy for dose escalation * BH-30643 monotherapy for dose expansion/optimization at doses determined from dose escalation data

    Drug: BH-30643

  • Experimental
    Phase 1 Combination Dose Escalation and Expansion

    * BH-30643 combo therapy with Carboplatin/Pemetrexed for dose escalation * BH-30643 combo therapy with Carboplatin/Pemetrexed for dose expansion /optimization at doses determined from dose escalation data

    Drug: BH-30643 combo therapy with Carboplatin/Pemetrexed

  • Experimental
    Phase 2

    BH-30643 administered at the RP2D dose determined in Phase 1

    Drug: BH-30643

Interventions

  • DrugBH-30643

    BH-30643 will be provided as either 10 mg or 40 mg capsules or tablets. Subjects will take BH-30643 orally depending on their dose level assignment.

  • DrugBH-30643 combo therapy with Carboplatin/Pemetrexed

    Drug pages: Carboplatin · Pemetrexed

    BH-30643 will be provided as either 10 mg or 40 mg capsules or tablets in combo therapy with Carboplatin/Pemetrexed. Subjects will take BH-30643 orally depending on their dose level assignment. Carboplatin/Pemetrexed will be administered according to standard of care

  • DrugBH-30643

    BH-30643 will be provided as either 10 mg or 40 mg capsules. Subjects will take BH-30643 orally depending on their dose level assignment

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)

    Assess dose-limiting toxicities (DLTs) as defined in the study protocol.

    Time frame: Within the first 21 days of the first dose of BH-30643.

  2. Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization)

    Determine the RP2D for Phase 2.

    Time frame: Within 21 days of last participant dosed during Dose Expansion/Optimization.

  3. Objective Response Rate (ORR) (Phase 2)

    Determine ORR as assessed by Blinded Independent Central Review (BICR).

    Time frame: Approximately 3 years after the first participant dosed.

Secondary outcomes

  1. Safety

    Assess incidence and severity of treatment-emergent adverse events (TEAEs), as defined by CTCAE, V5.0 (Phase 1 and Phase 2).

    Time frame: From enrollment through study completion, approximately 48 months.

  2. Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUClast) of BH-30643 for Single dose (Phase 1).

    Determine area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUClast) of BH-30643.

    Time frame: Predose and up to 24 hours postdose.

  3. Maximum observed plasma concentration (Cmax) of BH-30643 for Single dose (Phase 1).

    Determine maximum observed plasma concentration (Cmax) of BH-30643.

    Time frame: Predose and up to 24 hours postdose.

  4. Time to reach Cmax (Tmax) of BH-30643 for Single dose (Phase 1).

    Determine time to reach Cmax (Tmax) of BH-30643.

    Time frame: Predose and up to 24 hours postdose.

  5. Area under the plasma concentration-time curve at steady state (AUCss) of BH-30643 for multiple doses (Phase 1) at steady state.

    Determine area under the plasma concentration-time curve at steady state (AUCss) of BH-30643.

    Time frame: Predose and up to 24 hours postdose.

  6. Objective Response Rate (ORR)

    The ORR is defined as a complete response (CR) or partial response (PR) per RECIST v1.1 recorded from first treatment until disease progression or start of new anti-cancer therapy. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met.

    Time frame: From enrollment until the date of the first documented progression or death from any cause, whichever occurs first, assessed up to study ends or patient discontinue from the study, whichever occurs first (up to approximately 4 years).

  7. Disease Control Rate (DCR)

    The DCR is defined as the percentage of subjects whose therapeutic intervention has led to a CR, PR, or stable disease (SD).

    Time frame: From enrollment until the date of the first documented progression or death from any cause, whichever occurs first, assessed up to study ends or patient discontinue from the study, whichever occurs first (up to approximately 4 years).

  8. Time to Tumor Response (TTR)

    Time to tumor response (TTR) is defined for subjects with a confirmed objective response, as the time from the date of first treatment to the first documentation of objective response (CR or PR) which is subsequently confirmed.

    Time frame: From first dose to the first occurrence of response, assessed up to the date of first documented progression or death from any cause, whichever occurs first (up to approximately 4 years).

  9. Duration of Response (DOR)

    The DOR is defined, for subjects with an objective response per RECIST v1.1, as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first.

    Time frame: From first occurrence of response until the date of the first documented progression or death from any cause, whichever occurs first, assessed up to study end or patient discontinuation from the study, whichever occurs first (up to approximately 4 years)

  10. Progression-free Survival (PFS)

    The endpoint PFS is defined as the time from the date of the first treatment to the date of the first documentation of objective progression of disease or death due to any cause, whichever occurs first.

    Time frame: From enrollment until the date of the first documented progression or death from any cause, whichever occurs first, assessed up to study end or patient discontinuation from the study, whichever occurs first (up to approximately 4 years).

  11. Overall Survival

    Overall survival is defined as the time from the date of first treatment to the date of death due to any cause.

    Time frame: From enrollment until the date of death from any cause, assessed up to study end or patient discontinuation from the study, whichever occurs first (up to approximately 4 years).

  12. ERTC-QLC-C30

    Change from Baseline in Patient Reported Outcome European Organization for Research and Treatment Quality of Life Questionnaire (ERTC-QLC-C30) at Treatment Cycle 2 and beyond (Phase 2).

    Time frame: From enrollment until the end of treatment, up till patient discontinue from treatment due to any reason (up to approximately 4 years).

  13. NSCLC-SAQ

    Change from Baseline in Patient Reported Outcome Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) at Treatment Cycle 2 and beyond (Phase 2).

    Time frame: From enrollment until the end of treatment, up till patient discontinues treatment for any reason (up to approximately 4 years).

07

Study locations

43 of 43 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2029, 48 months after the start.

Of 311 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 48 months is below that.

Counting every sponsor, half of 434 studies reached it within 62 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 26, 2024
StartActual
Jan 9, 2025
Primary completionEst.
Jan 31, 2029
CompletionEst.
Jul 31, 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Cedars-Sinai Cancer at Cedars Sinai Medical Center · Los Angeles, United States
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    1 site added
    Show site
    • Cedars-Sinai Cancer at Cedars Sinai Medical Center · Los Angeles, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06706076
Lead sponsor
BlossomHill Therapeutics
Responsible party
Sponsor
First posted
Nov 26, 2024
Start date
Jan 9, 2025
Primary completion
Jan 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Sponsor Contact
Contact
clinicaltrials@bhtherapeutics.com
(858) 732-3880

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Pemetrexed

Start the discussion